Clinical trial
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV (M0) Resectable Cutaneous Squamous Cell Carcinoma
NCT06288191 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV (M0) Resectable Cutaneous Squamous Cell Carcinoma
- Lead sponsor
- Melanoma Institute Australia
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 21, 2024
- Completion date
- July 31, 2036
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.